Higher expression of beclin 1 in human meningiomas is related to better clinical outcome and pathological grade

APMIS. 2019 Dec;127(12):746-752. doi: 10.1111/apm.12995. Epub 2019 Oct 14.

Abstract

Meningiomas are common intracranial tumors, and most exhibit optimal prognosis; however, some meningiomas still recur and even develop malignant transformation in the following years, regardless of initial pathological grade. During these years, autophagy raises its significance in tumorigenesis and tumor suppression, both important for tumor development. The aim of this study was to elucidate the relationship between two autophagy markers, LC3B and beclin 1, with clinical and pathological parameters in patients with meningiomas. A total of 77 thin-sectioned slides, retrospectively collected from meningioma patients, were analyzed and correlated with clinicopathological parameters. We found that expression of beclin 1 rather than LC3B correlated to better prognosis, lower pathological grade, and longer survival. Furthermore, intensity of beclin 1 was also found to be significantly related to the pathological grade. These findings indicated that beclin 1 as a protective factor predicts better prognosis and plays the role of tumor suppression in meningiomas.

Keywords: LC3B; Meningioma; autophagy; beclin1; immunohistochemistry.

MeSH terms

  • Beclin-1 / genetics*
  • Beclin-1 / metabolism*
  • Female
  • Humans
  • Immunohistochemistry
  • Male
  • Meningeal Neoplasms / metabolism
  • Meningeal Neoplasms / mortality
  • Meningeal Neoplasms / physiopathology*
  • Meningioma / metabolism
  • Meningioma / mortality
  • Meningioma / physiopathology*
  • Microtubule-Associated Proteins / metabolism
  • Middle Aged
  • Prognosis
  • Retrospective Studies
  • Survival Rate

Substances

  • BECN1 protein, human
  • Beclin-1
  • MAP1LC3B protein, human
  • Microtubule-Associated Proteins